Given the crosstalk between PSMA and AR signaling pathways, an interesting phase III PSMAddition trial is evaluating the combination of AR signaling block (castration plus standard of care androgen receptor directed therapy) and 177Lu-PSMA-617 (6 cycles) as a first-line therapy for hormonal naïve metastatic prostate cancer (Table 1, NCT04720157). Here, AR is linked to metastatic prostate carcinoma.